We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+186.12%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$147M
AUM Growth
+$50.5M
Cap. Flow
-$12.7M
Cap. Flow %
-8.64%
Top 10 Hldgs %
79.38%
Holding
35
New
7
Increased
4
Reduced
6
Closed
5
Avg Time Held
4 quarters
Top 10 Avg Time Held
2.7 quarters
Top 20 Avg Time Held
3.5 quarters

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$6.2M
2
TERN icon
Terns Pharmaceuticals
TERN
+$3.1M
3
NERV icon
Minerva Neurosciences
NERV
+$2.63M
4
TNGX icon
Tango Therapeutics
TNGX
+$2.44M
5
DSGN icon
Design Therapeutics
DSGN
+$1.18M

Top Sells

Rank Stock Value
1
TRML icon
Tourmaline Bio
TRML
+$12.8M
2
CDTX icon
Cidara Therapeutics
CDTX
+$8.47M
3
INSM icon
Insmed
INSM
+$2.32M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.95M
5
KRYS icon
Krystal Biotech
KRYS
+$1.87M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TERN icon
1
DELISTED
Terns Pharmaceuticals
TERN
$25.7M 17.48%
637,095
+134,298
+27% +$3.1M
2022 Q3
13 quarters
PRAX icon
2
Praxis Precision Medicines
PRAX
$6.77B
$24.5M 16.62%
83,036
+33,285
+67% +$6.2M
2023 Q2
10 quarters
CDTX icon
3
DELISTED
Cidara Therapeutics
CDTX
$19.7M 13.37%
89,145
-52,384
-37% -$8.47M
2024 Q4
4 quarters
OCUL icon
4
Ocular Therapeutix
OCUL
$1.57B
$12.8M 8.68%
1,052,995
-112,211
-10% -$1.36M
2023 Q4
8 quarters
WHWK icon
5
Whitehawk Therapeutics
WHWK
$173M
$8.25M 5.6%
3,410,402
– –
2021 Q3
17 quarters
DRUG icon
6
Bright Minds Biosciences
DRUG
$518M
$6.59M 4.48%
84,477
-398
-0.5% -$26.6K
2024 Q4
4 quarters
CMPX icon
7
Compass Therapeutics
CMPX
$153M
$5.87M 3.99%
1,093,300
+253,210
+30% +$1.17M
2025 Q3
1 quarter
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$13.9B
$4.93M 3.35%
29,008
+3,894
+16% +$597K
2025 Q1
3 quarters
INSM icon
9
Insmed
INSM
$21.4B
$4.5M 3.06%
25,878
-12,714
-33% -$2.32M
2023 Q4
8 quarters
ARGX icon
10
argenx
ARGX
$52.1B
$4.08M 2.77%
4,851
-1,528
-24% -$1.31M
2024 Q2
6 quarters
SRZN icon
11
Surrozen
SRZN
$276M
$4.03M 2.74%
178,415
– –
2025 Q1
3 quarters
AMLX icon
12
Amylyx Pharmaceuticals
AMLX
$3.4B
$4.03M 2.73%
333,258
– –
2025 Q3
1 quarter
NERV icon
13
Minerva Neurosciences
NERV
$120M
$2.85M 1.94%
+709,500
New +$2.63M
2025 Q4
0 quarters
TNGX icon
14
Tango Therapeutics
TNGX
$3.71B
$2.51M 1.7%
+282,732
New +$2.44M
2025 Q4
0 quarters
TSHA icon
15
Taysha Gene Therapies
TSHA
$1.17B
$2.5M 1.7%
454,827
– –
2025 Q2
2 quarters
ZYME icon
16
Zymeworks
ZYME
$1.77B
$2.11M 1.43%
80,143
– –
2024 Q4
4 quarters
OCS icon
17
Oculis Holding
OCS
$460M
$2.03M 1.38%
101,777
– –
2025 Q1
3 quarters
DSGN icon
18
Design Therapeutics
DSGN
$612M
$1.42M 0.96%
+150,906
New +$1.18M
2025 Q4
0 quarters
INBX icon
19
Inhibrx
INBX
$1.25B
$1.29M 0.88%
16,377
– –
2025 Q3
1 quarter
UTHR icon
20
United Therapeutics
UTHR
$23.3B
$1.12M 0.76%
2,296
– –
2025 Q3
1 quarter
VSTM icon
21
Verastem
VSTM
$798M
$1.11M 0.75%
143,446
– –
2025 Q1
3 quarters
MAZE icon
22
Maze Therapeutics
MAZE
$1.47B
$829K 0.56%
+20,000
New +$687K
2025 Q4
0 quarters
MLTX icon
23
MoonLake Immunotherapeutics
MLTX
$873M
$781K 0.53%
+59,280
New +$699K
2025 Q4
0 quarters
STRO icon
24
Sutro Biopharma
STRO
$174M
$780K 0.53%
+67,451
New +$640K
2025 Q4
0 quarters
DNTH icon
25
Dianthus Therapeutics
DNTH
$4.26B
$689K 0.47%
16,708
-8,292
-33% -$321K
2025 Q3
1 quarter
1
2

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Acuta Capital Partners held 35 positions worth $147M, up 52% from $96.8M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Acuta Capital Partners withdrew a net $12.7M in Q4 2025, closing 5 positions and reducing 6 holdings. Its most notable exit was Tourmaline Bio, an estimated $12.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Acuta Capital Partners opened a new position in Minerva Neurosciences worth $2.85M.

  • Acuta Capital Partners's largest Q4 2025 buy was Minerva Neurosciences: 709,500 shares worth $2.85M.
  • Acuta Capital Partners added most to Praxis Precision Medicines in Q4 2025, an estimated $6.2M increase.
  • Acuta Capital Partners's biggest Q4 2025 reduction was Cidara Therapeutics, cutting an estimated $8.47M.
  • Acuta Capital Partners fully exited Tourmaline Bio in Q4 2025, selling an estimated $12.8M.
  • Acuta Capital Partners's ten largest holdings make up 79% of its $147M portfolio in Q4 2025.
  • Acuta Capital Partners opened 7 new positions and closed 5 in Q4 2025.
  • Acuta Capital Partners's portfolio value rose 52% quarter-over-quarter to $147M.

Based on Acuta Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.